Patents by Inventor Randall G. Rupp

Randall G. Rupp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180288998
    Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.
    Type: Application
    Filed: May 26, 2018
    Publication date: October 11, 2018
    Applicant: Noveome Biotherapeutics, Inc.
    Inventors: Richard A. Banas, David L. Steed, Randall G. Rupp, George L. Sing
  • Publication number: 20170035812
    Abstract: The invention is directed to a novel cell-derived composition having bone growth, regeneration, and repair promoting properties. In particular, the invention is directed to a novel cell-derived composition having bone growth, regeneration, and repair promoting properties termed Amnion-derived Cellular Cytokine Solution-B (ACCS-B). The invention is further directed to the use of this novel composition to promote bone growth and/or regeneration and/or repair.
    Type: Application
    Filed: October 10, 2016
    Publication date: February 9, 2017
    Applicant: Noveome Biotherapeutics, Inc.
    Inventors: Malcolm A Meyn, III, Christopher A Fried, Donna M Olejniczak, Randall G Rupp
  • Publication number: 20160367602
    Abstract: The invention is directed to methods for treating Hidradenitis Suppurativa. Specifically, the invention is directed to treating and reducing inflammation associated Hidradenitis Suppurativa by administering to a subject suffering from this condition novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).
    Type: Application
    Filed: September 1, 2016
    Publication date: December 22, 2016
    Applicant: Noveome Biotherapeutics, Inc.
    Inventors: George L. Sing, Randall G. Rupp, David L. Steed
  • Patent number: 9464272
    Abstract: The invention is directed to a cell-derived composition having bone growth, regeneration, and repair promoting properties. In particular, the invention is directed to a cell-derived composition having bone growth, regeneration, and repair promoting properties termed Amnion-derived Cellular Cytokine Solution-B (ACCS-B). The invention is further directed to the use of this composition to promote bone growth and/or regeneration and/or repair.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: October 11, 2016
    Assignee: STEMNION, INC.
    Inventors: Malcolm A Meyn, III, Christopher A Fried, Donna M Olejniczak, Randall G Rupp
  • Publication number: 20160220617
    Abstract: The invention is directed to methods for treating cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease. The invention is also directed to methods for preventing cartilage disorders and diseases including, but not limited to, degenerative disc disease. The field of the invention is further directed to reducing inflammation associated with cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease.
    Type: Application
    Filed: April 11, 2016
    Publication date: August 4, 2016
    Applicant: Noveome Biotherapeutics, Inc.
    Inventors: Donna M. Olejniczak, David L. Steed, Randall G. Rupp, George L. Sing
  • Patent number: 9314487
    Abstract: The invention is directed to methods for treating cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease. The invention is also directed to methods for preventing cartilage disorders and diseases including, but not limited to, degenerative disc disease. The field of the invention is further directed to reducing inflammation associated with cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease.
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: April 19, 2016
    Assignee: STEMNION, INC.
    Inventors: Donna M Olejniczak, David L Steed, Randall G Rupp, George L Sing
  • Publication number: 20160081329
    Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.
    Type: Application
    Filed: December 2, 2015
    Publication date: March 24, 2016
    Applicant: Stemnion, Inc.
    Inventors: Richard A. Banas, David L. Steed, Randall G. Rupp, George L. Sing
  • Publication number: 20160015785
    Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.
    Type: Application
    Filed: September 16, 2015
    Publication date: January 21, 2016
    Applicant: Stemnion, Inc.
    Inventors: Richard A. Banas, David L. Steed, Randall G. Rupp, George L. Sing
  • Publication number: 20160000874
    Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.
    Type: Application
    Filed: September 16, 2015
    Publication date: January 7, 2016
    Applicant: STEMNION, INC.
    Inventors: Richard A. Banas, David L. Steed, Randall G. Rupp, George L. Sing
  • Publication number: 20150196603
    Abstract: The invention is directed to novel cell compositions termed AMP-N cells. In particular, the invention is directed to novel AMP-N cell compositions and novel compositions derived from the AMP-N cells including, but not limited to, novel cell-derived conditioned medium, termed ACCS-N. The invention is further directed to novel methods for making the novel AMP-N cell and ACCS-N compositions as well as uses thereof.
    Type: Application
    Filed: August 2, 2013
    Publication date: July 16, 2015
    Applicant: STEMNION, INC.
    Inventors: Victoria Grammer, Malcolm A Meyn, III, Randall G. Rupp
  • Publication number: 20150166951
    Abstract: The invention is directed to a novel cell-derived composition having bone growth, regeneration, and repair promoting properties. In particular, the invention is directed to a novel cell-derived composition having bone growth, regeneration, and repair promoting properties termed Amnion-derived Cellular Cytokine Solution-B (ACCS-B). The invention is further directed to the use of this novel composition to promote bone growth and/or regeneration and/or repair.
    Type: Application
    Filed: December 11, 2014
    Publication date: June 18, 2015
    Applicant: STEMNION, INC.
    Inventors: Malcolm A Meyn, III, Christopher A Fried, Donna M Olejniczak, Randall G Rupp
  • Publication number: 20150079190
    Abstract: The invention is directed to immortalized cell compositions and compositions derived therefrom. The invention is further directed to methods of making and using such immortalized cell compositions and compositions derived therefrom. Such immortalized cell compositions include but are not limited to Immortalized Amnion-derived Multipotent Progenitor cells (herein referred to as I-AMP cells) and conditioned media derived therefrom (herein referred to as I-Amnion-derived Cellular Cytokine Solution or I-ACCS).
    Type: Application
    Filed: November 20, 2014
    Publication date: March 19, 2015
    Applicant: STEMNION, INC.
    Inventors: Randall G. Rupp, Linda O. Palladino
  • Publication number: 20150051147
    Abstract: The invention is directed to methods for treating Hidradenitis Suppurativa. Specifically, the invention is directed to treating and reducing inflammation associated Hidradenitis Suppurativa by administering to a subject suffering from this condition novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).
    Type: Application
    Filed: August 12, 2014
    Publication date: February 19, 2015
    Applicant: STEMNION, INC.
    Inventors: George L. Sing, Randall G. Rupp, David L Steed
  • Publication number: 20140341860
    Abstract: The invention is directed to methods for treating cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease. The invention is also directed to methods for preventing cartilage disorders and diseases including, but not limited to, degenerative disc disease. The field of the invention is further directed to reducing inflammation associated with cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease.
    Type: Application
    Filed: May 13, 2014
    Publication date: November 20, 2014
    Applicant: STEMNION, INC.
    Inventors: Donna M. Olejniczak, David L. Steed, Randall G. Rupp, George L. Sing
  • Publication number: 20140255904
    Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.
    Type: Application
    Filed: March 3, 2014
    Publication date: September 11, 2014
    Applicant: Stemnion, Inc.
    Inventors: Richard A. Banas, David L. Steed, Randall G. Rupp, George L. Sing
  • Patent number: 8647663
    Abstract: The invention is directed to a novel wound healing device. In particular, the invention is directed to a novel wound healing device comprising a suture or knitted mesh that has adsorbed onto it novel cellular factor-containing compositions (referred to herein as CFC), including Amnion-derived Cellular Cytokine Solution (referred to herein as ACCS) or Physiologic Cytokine Solutions (herein referred to as PCS), as well as methods of making and uses thereof.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: February 11, 2014
    Assignee: Stemnion, Inc.
    Inventors: David L. Steed, Randall G. Rupp, Howard C. Wessel
  • Patent number: 8642027
    Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs. The invention is further directed to methods of increasing time to ischemic injury in tissues and organs. Such methods utilize compositions comprising cells capable of modulating inflammatory responses, referred to herein as Inflammatory Response Modulating Cells (IRMCs). The IRMCs any be used directly or cell membranes derived from them may be used in practicing the methods of the invention. In addition, the IRMCs and IRMC membranes may be used alone or in combination with each other and/or in combination with various suitable active agents.
    Type: Grant
    Filed: August 25, 2011
    Date of Patent: February 4, 2014
    Assignee: Stemnion, Inc.
    Inventors: Richard A. Banas, David L. Steed, Randall G. Rupp
  • Publication number: 20130302262
    Abstract: Methods for preventing, reversing, ameliorating or treating dental diseases, disorders or injuries are provided. In particular, methods for preventing, reversing, ameliorating or treating dental diseases of the gingival (gums) and bone are provided. Such methods utilize novel compositions including, but not limited to, extraembryonic cytokine-secreting cells (herein referred to as ECS cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), and Physiologic Cytokine Solution (herein referred to as PCS), each alone or in combination with each other and/or other agents.
    Type: Application
    Filed: December 14, 2011
    Publication date: November 14, 2013
    Applicant: STEMNION, INC.
    Inventors: William J Golden, Randall G Rupp
  • Patent number: 8444417
    Abstract: Methods for preventing, reversing, ameliorating or treating dental diseases, disorders or injuries are provided. In particular, methods for preventing, reversing, ameliorating or treating dental diseases of the gingival (gums) and bone are provided. Such methods utilize novel compositions including, but not limited to, extraembryonic cytokine-secreting cells (herein referred to as ECS cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), and Physiologic Cytokine Solution (herein referred to as PCS), each alone or in combination with each other and/or other agents.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: May 21, 2013
    Assignee: Stemnion, Inc.
    Inventors: William J. Golden, Randall G. Rupp
  • Publication number: 20120315246
    Abstract: The invention is directed to novel compositions and methods for modulating inflammatory and/or immune responses. Such novel compositions are derived from extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as extraembryonic HLA-G positive or “EHP” cells) and Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells), alone or in combination with each other and/or in combination with various matrices and/or devices and/or other suitable active agents. The novel methods of modulating inflammatory and/or immune responses utilize such novel compositions.
    Type: Application
    Filed: June 1, 2012
    Publication date: December 13, 2012
    Inventors: Randall G. Rupp, Richard A. Banas